These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26686797)

  • 1. Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in Finland.
    Koskinen H; Mikkola H; Saastamoinen LK; Ahola E; Martikainen JE
    Value Health; 2015 Dec; 18(8):1105-12. PubMed ID: 26686797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland.
    Koskinen H; Ahola E; Saastamoinen LK; Mikkola H; Martikainen JE
    Health Econ Rev; 2014 Dec; 4(1):9. PubMed ID: 26054399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
    Lessing C; Ashton T; Davis PB
    J Prim Health Care; 2015 Jun; 7(2):94-101. PubMed ID: 26125054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment.
    Lessing C; Ashton T; Davis P
    Adm Policy Ment Health; 2015 Nov; 42(6):695-703. PubMed ID: 25331449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses.
    Leopold C; Zhang F; Mantel-Teeuwisse AK; Vogler S; Valkova S; Ross-Degnan D; Wagner AK
    Int J Equity Health; 2014 Jul; 13():53. PubMed ID: 25062657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
    Kaló Z; Muszbek N; Bodrogi J; Bidló J
    Health Policy; 2007 Mar; 80(3):402-12. PubMed ID: 16730848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
    Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of generic reference pricing on medicine cost in Slovenia: a retrospective study.
    Marđetko N; Kos M
    Croat Med J; 2018 Apr; 59(2):79-89. PubMed ID: 29740992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
    Håkonsen H; Horn AM; Toverud EL
    Health Policy; 2009 May; 90(2-3):277-85. PubMed ID: 19042052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A reference pricing system for Ireland.
    Usher C; Barry M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):675-7. PubMed ID: 23252350
    [No Abstract]   [Full Text] [Related]  

  • 17. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
    Lee IH; Bloor K; Hewitt C; Maynard A
    Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
    Robinson JC
    Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.